nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Unipolar Depression"

 

International Suicide Survivor Day
November 21, 2020   

Previous research suggests that suicidal ideation may be higher among military-associated youth versus youth in the general population. However, in 2019 the Department of Defense reported that according to data collected in 2017, the overall suicide rate among...
 Continue reading
Psilocybin-Assisted Therapy in Major Depressive Disorder
November 17, 2020   

Although the glutamatergic agent ketamine has been shown to provide rapid reductions in symptoms of depression and suicidality, the therapeutic effects of ketamine are short-lived and ketamine itself is associated with a toxicity and addiction liability. Psilocybin is a classic...
 Continue reading (Members only)
Evidence-based Suicide Prevention Strategies During and After the COVID-19 Pandemic
October 5, 2020   

Even before the 2020 COVID-19 pandemic, suicide was a major issue and concern, with approximately 800,000 people dying by suicide each year. Not only has COVID-19 caused an alarming number of deaths due to infection with the SARS-CoV-2 virus, for numerous reasons, the number of lives lost to suicide is also expected to increase because of the COVID-19 pandemic. Due to the economic shutdown and physical distancing measures...
 Continue reading (Members only)
Depression Symptoms Soar During Pandemic, Study Finds
September 28, 2020   

The coronavirus disease 2019 (COVID-19) pandemic has been a traumatic event that is compounded by the policies enacted to prevent its spread, which have introduced new life stressors and disrupted daily living for most people in the United States (US). Early evidence suggests that...
 Continue reading (Members only)
Antihypertensive Drugs Associated With Reduced Risk for Depression
September 11, 2020   

A list of nine antihypertensive medications were associated with decreased risk of depression in a recently published population-based study. The risk of a diagnosis of depression was evaluated in patients taking any of forty-one antihypertensive therapies in four major drug categories...
 Continue reading (Members only)
Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects
August 28, 2020   

Between 6% and 8% of United States pregnant women are prescribed antidepressants. However, concerns remain about the adverse effects of antidepressants on fetal and infant health, including birth defect risk after early pregnancy exposure. The current study addresses this concern by examining the...
 Continue reading
NEI Virtual Poster Library is Live!
July 13, 2020   

NEI has launched a Virtual Poster Library to fulfill the needs of poster presenters who had hoped to share their research and findings at medical conferences that have been cancelled due to the COVID-19 pandemic....
 Continue reading
Effects of Yoga on Depressive Symptoms
June 19, 2020   

A recent meta-analysis assessed whether physically active yoga is superior to waitlist control, treatment as usual, and attention control in alleviating depressive symptoms in individuals diagnosed with a mental disorder...
 Continue reading (Members only)
FDA Recalls Extended-Release Metformin Due to Detection of NMDA
June 5, 2020   

The Food and Drug Administration has asked companies to voluntarily recall a specific type metformin over a potential cancer risk. The FDA announced that a high level of N-Nitrosodimethylamine, which is linked to cancer, was found in...
 Continue reading (Members only)
A Randomized Proof-of-Mechanism Trial Applying the ‘Fast-Fail’ Approach to Evaluating κ-Opioid Antagonism as a Treatment for Anhedonia
April 15, 2020   

The first Fast-Fail trial funded by the National Institute of Mental Health has identified a target for treating anhedonia. The Fast-Fail Trials initiative aims to improve early phase drug development...
 Continue reading (Members only)
12345678910
Top of Page